SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corporation

Applied Digital is currently trending as investors brace for the latest quarterly earnings report, with the community actively debating whether the company can secure major hyperscaler deals to justify its significant infrastructure debt. While some investors remain cautious about volatility, many are betting on a potential short squeeze fueled by robust AI data center demand and aggressive expansion plans.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is seeing intense volatility following a highly contentious short commentary that claims competitors are eroding its enterprise market share, leading to a fierce debate between retail investors dismissing the claims as market manipulation and skeptics concerned about the company's premium valuation. While the broader market shows resilience, community discussion remains heavily polarized as traders weigh these growth threats against Palantir's entrenched role in mission-critical government and enterprise AI.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing intense selling pressure as investors react to a critical analyst downgrade and persistent concerns over declining delivery figures and execution risks. The community is actively debating the company's valuation, with many traders closely monitoring support levels while expressing frustration over the stock's inability to participate in the broader market's recent rally.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending as investors debate the impact of AI on its long-term business model, with the stock recently hitting 52-week lows despite strong institutional support and insider buying from leadership. The community is actively divided, with many debating if recent share price volatility represents a genuine valuation reset or an overreaction to fears that new AI agent technologies could displace traditional SaaS enterprise platforms.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging as the company announced a major new customer contract for its high-power wafer-level burn-in systems, fueling investor optimism regarding its expansion into silicon photonics and AI data center infrastructure. The community is actively debating the stock's valuation and the sustainability of its rapid price movement, with traders closely watching upcoming earnings as a critical catalyst for the stock's next move.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing significant community attention as investors debate its long-term potential following a recent business update and the disclosure of its 2026 revenue outlook. While some market participants express frustration over recent price volatility and cautious guidance, many investors remain bullish, viewing the company as an undervalued player in the quantum sector with strong institutional partnerships and long-term upside.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is at the center of investor focus following the initiation of a $25 billion accelerated share repurchase program, the largest in history. While the community is actively debating whether this massive capital return will serve as a permanent floor or if ongoing AI-driven disruption fears will continue to pressure the stock, market participants are closely watching for signs that this technical catalyst can break the stock's recent downtrend.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending due to significant volatility and investor speculation ahead of an upcoming FDA decision on their skin cancer drug, with community discourse heavily polarized between traders betting on a rejection and those hopeful for a reversal of fortune. Many participants are actively monitoring options flow and insider activity, debating whether the stock's recent price action is driven by an information leak or speculative positioning by institutional funds.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is currently trending as investors monitor its resilience amid broader retail sector volatility, with the community actively debating whether its premium valuation remains justified by consistent membership growth and operational efficiency. Sentiment is bolstered by the stock's role as a defensive hedge, while traders closely watch key psychological support levels and ongoing discussions regarding potential future catalysts like a stock split.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending following news of potential engineering delays for its upcoming foldable iPhone, fueling debate among investors over whether the stock is a buying opportunity at these levels. The community is actively discussing the stock's long-term product roadmap, the impact of patent litigation in the Chinese market, and whether the recent pullback is an artificial shakeout driven by algorithmic positioning.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July.</li><li>Following months of engagement between the company and the FDA, Replimune subsequently resubmitted its application in October with additional information, data and analyses.</li><li>RP1 is Replimune’s lead product candidate.</li></ul>Shares of Replimune Group Inc (REPL) fell 15% on Wednesday as the deadline for the U.S. Food and Drug Administration’s decision on its skin cancer therapy RP1 draws close.If losses hold, REPL is on track for its worst session in nearly seven months.The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10. RP1 is Replimune’s lead product candidate.<h2 class="st-heading-2">RP1’s Past Issues</h2>In late July 2025, the FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency said in the letter that it is unable to approve the application in its present form, and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.Following months of engagement between the company and the FDA, Replimune subsequently resubmitted its application in October with additional information, data, and analyses.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at extremely high levels. Retail chatter around the stock has increased 171% over the past seven days, Stocktwits data showed.A retail user said that the FDA might ask for a fresh trial for approval, pitching the chances for a green light from the agency at below 20%.<stembedurl>https://www.stocktwits.com/BioRocket/message/649736736</stembedurl>Yet another user dismissed concerns about trial design.<stembedurl>https://www.stocktwits.com/pblegend66/message/649729070</stembedurl>Another user opined that the stock can either triple or wipe out a majority of its value after the FDA decision.<stembedurl>https://www.stocktwits.com/LilJimmy007/message/649726397</stembedurl><a href="https://stocktwits.com/symbol/REPL">REPL stock</a> has fallen 7% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/tron-taps-86-billion-stablecoin-liquidity-via-hyperlane-across-150-chains-after-justin-sun-s-ai-push/cZJf39TRIAk">TRON Taps $86 Billion Stablecoin Liquidity Via Hyperlane Across 150 Chains, After Justin Sun’s AI Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug

The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10.

Equity

The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10.


Replimune Group (NASDAQ:REPL) Stock Price Down 6.7% Following Insider Selling

Replimune Group (NASDAQ:REPL) Shares Down 6.7% After Insider Selling...

Christopher Sarchi Sells 6,500 Shares of Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) insider Christopher Sarchi sold 6,500 shares of the company's stock in a transaction on Thursday, April 2nd. The stock was sold at an average...

Replimune Group (NASDAQ:REPL) Insider Christopher Sarchi Sells 6,500 Shares

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) insider Christopher Sarchi sold 6,500 shares of the firm's stock in a transaction on Thursday, April 2nd. The shares were sold at an average...

<ul class="summary-bullets"><li>The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July.</li><li>Following months of engagement between the company and the FDA, the company subsequently resubmitted its application in October with additional information, data and analyses.</li></ul> Shares of Replimune Group Inc (REPL) closed 11% higher on Thursday as the deadline for the U.S. Food and Drug Administration’s decision on its skin cancer therapy RP1 draws close.The FDA is slated to decide on the company’s application for RP1 in the treatment of advanced melanoma by April 10. RP1 is Replimune’s lead product candidate.<h2 class="st-heading-2">RP1’s Past Issues</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/replimune-sarepta-capricor-stocks-surge-after-vinay-prasad-fda-exit/choXJLOR5Cg">issued</a> a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July.The agency said in the letter that it is unable to approve the application in its present form and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.Following months of engagement between the company and the FDA, the company subsequently resubmitted its application in October with additional information, data and analyses.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that shareholders are setting up to be disappointed like the last time when RP1 was denied approval.<stembedurl>https://www.stocktwits.com/TopCharts/message/649353360</stembedurl>Yet another expressed doubts about the FDA approving the drug, opining that a fresh trial would be needed for the same.<stembedurl>https://www.stocktwits.com/Steve_TheBull_Rogers/message/649347582</stembedurl>According to data from Koyfin, five of the seven analysts covering REPL stock rate it ‘Buy’ or higher while two rate it a ‘Hold’. The 12-month average price target on the stock is $12.86, representing a potential upside of about 53%. &nbsp;<a href="https://stocktwits.com/symbol/REPL">REPL stock</a> has fallen 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-sbac-stock-rallying-today/cZ7UR5SRI8r">Why Is SBAC Stock Rallying Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Rallies In Anticipation Of FDA Decision On Skin Cancer Drug

Replimune Group (NASDAQ:REPL) Shares Up 7.2% - Should You Buy?

Replimune Group (NASDAQ:REPL) Trading Up 7.2% - Time to Buy...

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.

Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Hold" by Analysts

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been given an average recommendation of "Hold" by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two...

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Corcept jumps after FDA approves Lifyorli combo for platinum-resistant ovarian cancer, marking the first-of-its-kind treatment.

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.

Patrick OShaughnessy - @patrick_oshag on X

Citrini - @Citrini7 on X

Bucco Capital - @buccocapital on X

Joe Weisenthal - @TheStalwart on X

The must-watch individual or show that brings entertainment to finance. This award celebrates the content you look forward to daily - bringing a sharp market edge to engaging discussions. 

Stocktwits

Stocktwits Polls

Traders are closely tracking the looming April 10th FDA decision for the firm's lead drug candidate.

Investors are debating the likelihood of a Complete Response Letter after reports surfaced regarding potential data inadequacies.

Heightened volatility is driving aggressive volume in puts and calls as market participants hedge for a binary event.

Recent Form 4 filings and persistent selling by company officers have fueled bearish sentiment and skepticism.

REPL
Replimune Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest REPL News

REPLReplimune Group Inc